sarcomere function with consequences for in vivo cardiac performance. The functional role of cMyBP-C is tightly regulated by kinase-mediated phosphorylation, of which protein kinase A (PKA)-mediated phosphorylation is important during cardiac stress and exercise. To date, three serines have been identified on which cMyBP-C can be phosphorylated in vivo, all of which are located in the cardiac isoform specific M region, i.e. Ser273, Ser282 and Ser 302. However, previous experiments have indicated that at least one more phosphorylation site should exist in humans. The aim of the present study was to identify the unknown phosphorylation site on human cMyBP-C. cMyBP-C was semi-purified from human non-failing donor and end-stage failing cardiac tissue. Tandem mass spectrometry was used to identify phosphorylation sites. Besides the already known Ser282 site, a phosphorylation site was detected on Ser133 in donor tissue. For characterization of this site, a phosphospecific antibody was developed. Levels of Ser133 phosphorylation are lower in end-stage heart failure samples as well as in samples from hypertrophic and dilated cardiomyopathy patients compared to donor. Initial experiments suggest that unlike the three previously known phosphorylation sites, Ser133 is not phosphorylated by PKA. In conclusion, we identified a fourth phosphorylation site (Ser133) in human cMyBP-C, which is present in the Pro-Ala rich region that links the C0 and C1 domains. This site is less phosphorylated in various cardiac pathologies and does not seem to be a target of PKA. Supported by the 7 th Framework Program of the European Union (''BIG-HEART,'' grant agreement 241577). Cardiac myosin binding protein-C (cMyBP-C), a sarcomeric protein with 11 domains-C0-C10, binds myosin LMM via its C-terminus, while its N-terminus binds both myosin S2 and actin. These N-terminal interactions can be attenuated by phosphorylation of serines within the C1-C2 linker. In vivo, cMyBP-C exists in a range of phosphorylation states, which may alter its regulation of actomyosin. Therefore, N-terminal fragments (C0-C3) of cMyBP-C were bacterially expressed with one or more phosphorylatable serines (S273, S282, S302) mutated to either alanines to mimic dephosphorylation or aspartic acids as phosphomimetics. Using C0-C3 fragments that were effectively mono-, di-or tri-phosphorylated, we characterized how the extent of cMyBP-C phosphorylation modulated the the force:velocity relationship generated by a small ensemble (~8 motors) of skeletal muscle myosin in the loadclamped laser trap assay. Mono-phosphorylated C0-C3 inhibited unloaded velocity by 70% as did unphosphorylated C0-C3, while di-and triphosphorylated constructs were indistinguishable and less inhibitory (30%). Maximal force was unaffected by the extent of phosphorylation. Thus, the un-and mono-phosphorylated C0-C3 constructs depressed the force-velocity relationship, which was well fitted by a modified Hill equation containing an assumed viscous load due to C0-C3 binding to actin (Weith et al., 2011) . In addition, both un-and mono-phosphorylated C0-C3 reduced peak power bỹ 40%, while neither di-nor tri-phosphorylated C0-C3 had any effect on peak power. cMyBP-C phosphorylation appears to modulate cMyBP-C's inhibition of actomyosin power generation in an ''on/off'' manner.
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Mechanical Stability of the Cardiac Myosin Binding Protein-C (CMybP-C) Motif is Phosphorylation-Dependent Arthur J. Michalek 1 , James Gulick 2 , Jeffrey Robbins 2 , David M. Warshaw 1 .
1 University of Vermont, Burlington, VT, USA, 2 Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Enhanced cardiac contractility results from phosphorylation within the cMyBP-C motif domain by affecting the interaction of cMyBP-C's N-terminus with actin and/or myosin. We investigated whether motif (i.e. C1C2 linker) phosphorylation alters its structural conformation by characterizing the forceextension behavior of expressed N-terminal cMyBP-C fragments (i.e.C0C3) that contain the motif using atomic force spectroscopy. Proteins were adsorbed onto glass slides, bound non-specifically to SiNi AFM probes, and stretched at 700nm/s. Force-extension traces showed the characteristic sawtooth shape of unfolding immunoglobulin domains, and were well fitted by the wormlike chain model. The model fits produced a median persistence length of 0.36nm and an average C0C3 contour length of 71.5nm, suggesting that the motif is disordered and freely extensible when unphosphorylated. PKA phosphorylation did not change immunoglobulin unfolding force or persistence length but decreased the contour length by 27nm, suggesting that the motif assumed a folded configuration that is stable under load. This was investigated further by varying the extent of phosphorylation using phosphomimetic mutants, in which serines 273, 282, and 302 were replaced with different combinations of alanines or aspartic acids in order to mimic the unphosphorylated and phosphorylated states respectively. While substitution with all alanines or all aspartic acids produced similar results to the control and PKA treated fragments respectively, phosphorylation at only one or two sites did not reduce contour length significantly. This implies that phosphorylation at all three sites is required for motif folding to be stable under load, while partial phosphorylation may result in a fold which is readily extended at low force. In conclusion, cMyBP-C phosphorylation could modulate the cMyBP-C's N-terminal domain interactions with actin and/or myosin by folding the motif in such a way that binding sites for actin and/or myosin are hidden. Titin is a giant protein that functions as a molecular spring and contributes to the passive diastolic stiffness of the left ventricle (LV). Titin's spring region consists of three sequence elements: the tandem Ig, the N2B and the PEVK elements. Mouse models exist in which either of the latter two elements (N2B KO, PEVK KO) has been deleted, but considering that these elements are also likely to play roles in signaling, we made a model in which we deleted 2/3 of the proximal tandem Ig element (IGKO), a region that is not known to contain signaling functions. Homozygous KO mice survive to adulthood and are fertile with no change in LV Weight to Body Weight (LVW/BW) ratio (3.6750.07mg/g WT vs 3.5150.04mg/g IgKO). A custom titin exon microarray confirmed the deletion of the expected exons with no other changes. Gel electrophoresis showed that the IGKO expresses an 88kDa smaller titin isoform but no other changes in isoform expression. Immuno-electron microscopy indicates that the remaining spring elements extend to a higher degree than in WT myocardium. Mechanical measurements in cardiomyocytes (see also poster by Methawasin) and myofibers show that the deletion increases passive stiffness in titin in a sarcomere length dependence manner, without adaptations in the passive stiffness of the extracellular matrix. Initial isolated intact heart data and in-vivo pressure volume measurement suggest that the IGKO has increased stiffness in-vivo. Further phenotypic characterization is currently underway. In summary, shortening the proximal tandem Ig element of titin produces a diastolic stiffness phenotype. Tubulin has been recently identified as a powerful regulator of voltage dependent anion channel (VDAC). Dimeric tubulin induces reversible blockage of VDAC reconstituted into planar lipid membranes and blocks the flux of ATP/ADP across the mitochondrial outer membrane. Here we show that phosphorylation of VDAC by cytosolic kinases protein kinase A (PKA) and glycogen synthase kinase-3b (GSK3b) increases the on-rate of tubulin binding by orders of magnitude, but only for tubulin at the cis (or cytosolic) side of the membrane. This and the fact that the basic properties of VDAC, such as single-channel conductance and selectivity, remained unaltered by phosphorylation allowed us to suggest the phosphorylation regions positioned on the cytosolic loops of VDAC and establish channel orientation in our reconstitution experiments. Experiments on human hepatoma cells HepG2 are in agreement with our findings that phosphorylation state of VDAC determines its blockage by tubulin. When HepG2 cells were treated with the microtubule-destabilizing 436a Tuesday, February 28, 2012 
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